These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 27517841)

  • 21. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
    Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
    Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
    An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
    Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
    Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
    Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
    Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
    Oh SY; Lee S; Huh SJ; Lee J; Kim ST; Park SH; Lim HY; Kang WK; Kang BW; Kim JG; Lee HJ; Kim JH; Kang JH; Kim H
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):501-508. PubMed ID: 30535535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment.
    Shitara K; Yatabe Y; Matsuo K; Sugano M; Kondo C; Takahari D; Ura T; Tajika M; Ito S; Muro K
    Gastric Cancer; 2013 Apr; 16(2):261-7. PubMed ID: 22797858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2-positive gastric cancer showing marked thickening of the gastric wall on ultrasonographic and computed tomographic scans. a chance phenomenon or a specific behaviour of this cancer type? Report of three cases.
    DI Cicilia R; Mordenti P; Anselmi E; Paties C; Carella E; Cavanna L
    Anticancer Res; 2014 Sep; 34(9):5083-6. PubMed ID: 25202095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
    Song Y; Huang J; Wang JW
    Chin J Cancer; 2010 Jan; 29(1):76-81. PubMed ID: 20038314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
    Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast-Enhanced CT Texture Analysis: a New Set of Predictive Factors for Small Cell Lung Cancer.
    Chen C; Ou X; Li H; Zhao Y; Zhao F; Zhou S; Ma X
    Mol Imaging Biol; 2020 Jun; 22(3):745-751. PubMed ID: 31429049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.
    Ock CY; Lee KW; Kim JW; Kim JS; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Kim WH; Bang YJ; Oh DY
    Clin Cancer Res; 2015 Jun; 21(11):2520-9. PubMed ID: 25712681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.
    Hedner C; Tran L; Borg D; Nodin B; Jirström K; Eberhard J
    Histopathology; 2016 Jan; 68(2):230-40. PubMed ID: 26016514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
    Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
    Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastric cancer: texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker.
    Giganti F; Antunes S; Salerno A; Ambrosi A; Marra P; Nicoletti R; Orsenigo E; Chiari D; Albarello L; Staudacher C; Esposito A; Del Maschio A; De Cobelli F
    Eur Radiol; 2017 May; 27(5):1831-1839. PubMed ID: 27553932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
    Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
    Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
    Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
    Lee CK; Kim SS; Park S; Kim C; Heo SJ; Lim JS; Kim H; Kim HS; Rha SY; Chung HC; Park S; Jung M
    Oncotarget; 2017 May; 8(19):31169-31179. PubMed ID: 28415714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas.
    Woo CG; Ho WJ; Park YS; Park SR; Ryu MH; Jung HY; Kang YK
    Pathology; 2017 Jan; 49(1):38-43. PubMed ID: 27931719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
    Daum O; Skálová A; Rozkos T; Laco J
    Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.